期刊
FRONTIERS IN IMMUNOLOGY
卷 12, 期 -, 页码 -出版社
FRONTIERS MEDIA SA
DOI: 10.3389/fimmu.2021.768133
关键词
resolution; adaptive immunity; autoimmunity; T cell; therapy; specialized pro-resolving lipid mediators (SPMs); chronic inflammation
类别
资金
- EFSD/JDRF/Lilly European Programme in Type 1 Diabetes Research 2019
- Agence Nationale de la Recherche [ANR-17-CE17-0004, ANR-18-IDEX-0001, ANR-11-LABX-0021]
- Fondation pour la Recherche Medicale [EQU20193007831]
- Association des Jeunes Diabetiques
- Innovative Medicines Initiative 2 Joint Undertaking from the EU Horizon 2020 program [115797, 945268]
- European Federation of Pharmaceutical Industries and Associations
- JDRF
- Leona M. and Harry B. Helmsley Charitable Trust
- Italian Ministry of Health [GR-2016-02362380]
- Italian Foundation of Multiple Sclerosis [FISM 2017/R/08]
- MAI Award [MAI-VC-2021]
- Conseil Regional de Franche-Comte [AAP 2019]
- BPI France [DOS0060162/00]
- European Union through the European Regional Development Fund of the Region Bourgogne-Franche-Comte [FC0013440]
- Agence Nationale de la Recherche (ANR) [ANR-17-CE17-0004] Funding Source: Agence Nationale de la Recherche (ANR)
This article discusses the role of bioactive lipids in regulating inflammatory responses and the importance of specialized pro-resolving lipid mediators in controlling chronic inflammation. Additionally, it explores their potential application as new biological markers for disease diagnosis, progression, and therapeutic tools to regulate inflammatory and autoimmune diseases.
Both the initiation and the resolution of inflammatory responses are governed by the sequential activation, migration, and control/suppression of immune cells at the site of injury. Bioactive lipids play a major role in the fine-tuning of this dynamic process in a timely manner. During inflammation and its resolution, polymorphonuclear cells (PMNs) and macrophages switch from producing pro-inflammatory prostaglandins and leukotrienes to specialized pro-resolving lipid mediators (SPMs), namely, lipoxins, resolvins, protectins, and maresins, which are operative at the local level to limit further inflammation and tissue injury and restore homeostasis. Accumulating evidences expand now the role and actions of these lipid mediators from innate to adaptive immunity. In particular, SPMs have been shown to contribute to the control of chronic inflammation, and alterations in their production and/or function have been associated with the persistence of several pathological conditions, including autoimmunity, in human and experimental models. In this review, we focus on the impact of pro-resolving lipids on T cells through their ability to modulate T-cell responses. In particular, the effects of the different families of SPMs to restrain effector T-cell functions while promoting regulatory T cells will be reviewed, along with the underlying mechanisms. Furthermore, the emerging concept of SPMs as new biological markers for disease diagnostic and progression and as putative therapeutic tools to regulate the development and magnitude of inflammatory and autoimmune diseases is discussed.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据